Gilles Morali
Overview
Explore the profile of Gilles Morali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
27
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amer J, Salhab A, Doron S, Morali G, Safadi R
Cytometry A
. 2018 Mar;
93(4):427-435.
PMID: 29517852
Hepatic stellate cells (HSCs) are a central fibrogenic cell type that contributes to collagen accumulation during chronic liver disease. Peripheral blood lymphocytes from HCV patients are phagocytized by HSCs and...
2.
Zelber-Sagi S, Ratziu V, Zvibel I, Goldiner I, Blendis L, Morali G, et al.
Eur J Gastroenterol Hepatol
. 2012 Jan;
24(3):262-9.
PMID: 22246329
Background And Aim: Leptin and adiponectin have been implicated in the development of nonalcoholic fatty liver disease (NAFLD). However, the usefulness of adipocytokines as a screening tool for nonalcoholic steatohepatitis...
3.
Morali G, Maor Y, Klar R, Braun M, Ben Ari Z, Bujanover Y, et al.
Isr Med Assoc J
. 2007 Sep;
9(8):588-91.
PMID: 17877064
Background: The Fibrotest-Actitest is a six-parameter scoring system that allows quantification of liver fibrosis and inflammation. This test has been validated by several studies in hepatitis B and C viruses...
4.
Bar-Gil Shitrit A, Kramer M, Bakal I, Morali G, Ben Ari Z, Shitrit D
Ann Thorac Surg
. 2006 Apr;
81(5):1851-2.
PMID: 16631684
Background: Several reports have shown the efficacy of prophylactic lamivudine treatment for hepatitis B virus (HBV) infection in liver and renal transplantations. No data are available, however, after lung transplantation....
5.
Morali G, Bar-Gil Shitrit A, Eran M, Freier S, Reinus C, Braverman D
Hepatogastroenterology
. 2005 Oct;
52(65):1511-5.
PMID: 16201108
Background/aims: IGF-I levels are reduced in cirrhotic patients. However, it is not known whether this decreased level is the result of reduced hepatic production or modified bioavailability secondary to decreased...
6.
Morali G, Safadi R, Pappo O, Jurim O, Shouval D
Isr Med Assoc J
. 2003 Jan;
4(12):1152-3.
PMID: 12516915
No abstract available.